if CEO is in US and still not delivering then it is even worst...

if CEO is in US and still not delivering then it is even worst then what I thought and warrant urgent replacement !

see you are making my point even more stronger ... !!

what is ill informed is that you have been ignoring the fact of cash burning by company and increase in benefit at time nothing delivered that can create value to shareholders apart form ATM facility so they keep getting higher pay.. !

There has been 20% increase in remuneration between 2022 and 2023 which is not above inflation but way outside what a company with poor revenue should be payig to anyone for that matter in my opinion.



Also, what was the meaning of all of the money ploughed into the company? how much was it? $100m or $200m ?

so total based on below roughly $105m collected so far and now we have another $30m available.. on top of this if required.

Biotech eats lots of money to be commercialise and i get that point but keep having high cashburn after FDA approval & code approval the company is still not getting into revenue stream but instead telling market we might need another 30m so we arranged for it is dumb.. in my opinion.